Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.

Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Jul;32(7):768-76. doi: 10.1097/INF.0b013e318292f425.

PMID:
23538521
[PubMed - indexed for MEDLINE]
2.

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ.

Vaccine. 2012 Apr 16;30(18):2831-8. doi: 10.1016/j.vaccine.2012.02.046. Epub 2012 Mar 3.

PMID:
22394992
[PubMed - indexed for MEDLINE]
3.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
[PubMed - indexed for MEDLINE]
4.

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.

Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F.

Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22.

PMID:
20033465
[PubMed - indexed for MEDLINE]
5.

Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.

Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.

Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.

PMID:
23114372
[PubMed - indexed for MEDLINE]
6.

The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age.

Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Clutterbuck EA, Ohene-Kena B, Klinger CL, Odrljin T, Pollard AJ.

Vaccine. 2013 May 7;31(20):2441-8. doi: 10.1016/j.vaccine.2013.03.036. Epub 2013 Apr 6.

PMID:
23566945
[PubMed - indexed for MEDLINE]
7.
8.

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1892-903. doi: 10.4161/hv.22166. Epub 2012 Oct 2.

PMID:
23032159
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J.

Eur J Pediatr. 2013 May;172(5):601-12. doi: 10.1007/s00431-012-1924-0. Epub 2013 Jan 11.

PMID:
23307281
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
[PubMed - indexed for MEDLINE]
11.

One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.

Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2013 Jul;32(7):760-7. doi: 10.1097/INF.0b013e31828693c5.

PMID:
23348814
[PubMed - indexed for MEDLINE]
12.

Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.

Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P.

Pediatr Infect Dis J. 2012 Jan;31(1):64-71. doi: 10.1097/INF.0b013e31823dce5c. Erratum in: Pediatr Infect Dis J. 2012 Oct;31(10):1105.

PMID:
22094635
[PubMed - indexed for MEDLINE]
13.

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.

PMID:
19116603
[PubMed - indexed for MEDLINE]
14.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

PMID:
19812260
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

PMID:
19476428
[PubMed - indexed for MEDLINE]
Free Article
16.

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM.

Hum Vaccin Immunother. 2012 Jul;8(7):866-72. doi: 10.4161/hv.20229. Epub 2012 Apr 9.

PMID:
22485049
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.

Sikkema DJ, Friedman KE, Corsaro B, Kimura A, Hildreth SW, Madore DV, Quataert SA.

Clin Diagn Lab Immunol. 2000 Sep;7(5):764-8.

PMID:
10973451
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.

Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D; HibMenCY-TT 005 Study Group.

Pediatr Infect Dis J. 2010 Jan;29(1):48-52. doi: 10.1097/INF.0b013e3181c3ce88.

PMID:
20035207
[PubMed - indexed for MEDLINE]
19.

Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V.

Vaccine. 2007 Oct 10;25(41):7233-7. Epub 2007 Aug 1.

PMID:
17707957
[PubMed - indexed for MEDLINE]
20.

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).

Østergaard L, Van der Wielen M, Bianco V, Miller JM.

Int J Infect Dis. 2013 Mar;17(3):e173-6. doi: 10.1016/j.ijid.2012.10.001. Epub 2012 Dec 13.

PMID:
23246368
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk